

## CLNE0029: Clinical neuroscience of neurodegenerative diseases

[View Online](#)

---

1.

Clarke C, Howard R, Rossor M, Shorvon SD, editors. Neurology: a Queen Square textbook [Internet]. Second edition. Chichester, West Sussex, UK: Wiley Blackwell; 2016. Available from: <https://onlinelibrary.wiley.com/doi/book/10.1002/9781118486160>

2.

McCarthy RA, Warrington EK. Cognitive neuropsychology: a clinical introduction [Internet]. San Diego, California: Academic Press, Inc; 1990. Available from: [http://ucl.alma.exlibrisgroup.com/view/action/uresolver.do?operation=resolveService&package\\_service\\_id=2909618430004761&institutionId=4761&customerId=4760](http://ucl.alma.exlibrisgroup.com/view/action/uresolver.do?operation=resolveService&package_service_id=2909618430004761&institutionId=4761&customerId=4760)

3.

Rossor M, Growdon JH. The dementias 2 [Internet]. [Place of publication not identified]: Butterworth Heinemann/Elsevier; 2007. Available from: [http://ucl.alma.exlibrisgroup.com/view/action/uresolver.do?operation=resolveService&package\\_service\\_id=2909618250004761&institutionId=4761&customerId=4760](http://ucl.alma.exlibrisgroup.com/view/action/uresolver.do?operation=resolveService&package_service_id=2909618250004761&institutionId=4761&customerId=4760)

4.

Hodges JR. Cognitive assessment for clinicians [Internet]. 3 ed. [Oxford]: Oxford University Press; 2017. Available from: <http://dx.doi.org/10.1093/med/9780198749189.001.0001>

5.

Kandel ER, Schwartz JH, Jessell TM, Siegelbaum S, Hudspeth AJ, editors. Principles of neural

science [Internet]. Fifth edition. New York: McGraw Hill Medical; 2013. Available from: [http://ucl.alma.exlibrisgroup.com/view/action/uresolver.do?operation=resolveService&package\\_service\\_id=2909605810004761&institutionId=4761&customerId=4760](http://ucl.alma.exlibrisgroup.com/view/action/uresolver.do?operation=resolveService&package_service_id=2909605810004761&institutionId=4761&customerId=4760)

6.

Husain M. Oxford textbook of cognitive neurology and dementia [Internet]. Husain M, Schott JM, Kennard C, editors. [Oxford]: Oxford University Press; 2016. Available from: [http://ucl.alma.exlibrisgroup.com/view/action/uresolver.do?operation=resolveService&package\\_service\\_id=2909605720004761&institutionId=4761&customerId=4760](http://ucl.alma.exlibrisgroup.com/view/action/uresolver.do?operation=resolveService&package_service_id=2909605720004761&institutionId=4761&customerId=4760)

7.

Alzheimer's Facts and Figures Report | Alzheimer's Association [Internet]. Available from: <https://www.alz.org/alzheimers-dementia/facts-figures>

8.

Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Molecular Medicine. 2016 Jun;8(6):595–608.

9.

Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. The Lancet Neurology. 2014 Jun;13(6):614–29.

10.

Loy CT, Schofield PR, Turner AM, Kwok JB. Genetics of dementia. The Lancet. 2014 Mar;383(9919):828–40.

11.

Karran E, Hardy J. Anti-amyloid Therapy for Alzheimer's Disease — Are We on the Right Road? New England Journal of Medicine. 2014 Jan 23;370(4):377–8.

12.

Johnson KA, Fox NC, Sperling RA, Klunk WE. Brain Imaging in Alzheimer Disease. Cold Spring Harbor Perspectives in Medicine. 2012 Apr 1;2(4):a006213–a006213.

13.

Ross CA, Aylward EH, Wild EJ, Langbehn DR, Long JD, Warner JH, et al. Huntington disease: natural history, biomarkers and prospects for therapeutics. Nature Reviews Neurology. 2014 Apr;10(4):204–16.

14.

Bates GP, Dorsey R, Gusella JF, Hayden MR, Kay C, Leavitt BR, et al. Huntington disease. Nature Reviews Disease Primers. 2015 Apr 23;

15.

Wild EJ, Tabrizi SJ. Therapies targeting DNA and RNA in Huntington's disease. The Lancet Neurology. 2017 Oct;16(10):837–47.

16.

Carroll JB, Bates GP, Steffan J, Saft C, Tabrizi SJ. Treating the whole body in Huntington's disease. The Lancet Neurology. 2015 Nov;14(11):1135–42.

17.

Tabrizi SJ, Scahill RI, Durr A, Roos RA, Leavitt BR, Jones R, et al. Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: the 12-month longitudinal analysis. The Lancet Neurology. 2011 Jan;10(1):31–42.

18.

Tabrizi SJ, Reilmann R, Roos RA, Durr A, Leavitt B, Owen G, et al. Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data. The Lancet Neurology. 2012 Jan;11(1):42–53.

19.

Tabrizi SJ, Scahill RI, Owen G, Durr A, Leavitt BR, Roos RA, et al. Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data. *The Lancet Neurology*. 2013 Jul;12(7):637–49.

20.

Jones L, Houlden H, Tabrizi SJ. DNA repair in the trinucleotide repeat disorders. *The Lancet Neurology*. 2017 Jan;16(1):88–96.

21.

Rossor M, Collinge J, Fox N, Mead S, Mummery C, Rohrer J, et al. Dementia and Cognitive Impairment. In: Clarke C, Howard R, Rossor M, Shorvon S, editors. *Neurology* [Internet]. Chichester, UK: John Wiley & Sons, Ltd; 2016. p. 289–336. Available from: <http://doi.wiley.com/10.1002/9781118486160.ch8>

22.

Rossor MN, Fox NC, Mummery CJ, Schott JM, Warren JD. The diagnosis of young-onset dementia. *The Lancet Neurology*. 2010 Aug;9(8):793–806.

23.

Schott JM, Fox NC, Rossor MN. Assessment and investigation of the cognitively impaired adult. In: Husain M, Schott JM, editors. *Oxford Textbook of Cognitive Neurology and Dementia* [Internet]. Oxford University Press; 2016. p. 221–30. Available from: <http://oxfordmedicine.com/view/10.1093/med/9780199655946.001.0001/med-9780199655946-chapter-21>

24.

Green AJE. RT-QulC: a new test for sporadic CJD. *Practical Neurology*. 2018 Oct 3;

25.

Collinge J. Mammalian prions and their wider relevance in neurodegenerative diseases.

Nature. 2016 Nov 9;539(7628):217–26.

26.

Mead S, Rudge P. CJD mimics and chameleons. Practical Neurology. 2017 Apr;17(2):113–21.

27.

Walker Z, Possin KL, Boeve BF, Aarsland D. Lewy body dementias. The Lancet. 2015 Oct;386(10004):1683–97.

28.

Halliday GM, Holton JL, Revesz T, Dickson DW. Neuropathology underlying clinical variability in patients with synucleinopathies. Acta Neuropathologica. 2011 Aug;122(2):187–204.

29.

Barker RA, Williams-Gray CH. Review: The spectrum of clinical features seen with alpha synuclein pathology. Neuropathology and Applied Neurobiology. 2016 Feb;42(1):6–19.

30.

Bras J, Guerreiro R, Darwent L, Parkkinen L, Ansorge O, Escott-Price V, et al. Genetic analysis implicates APOE, SNCA and suggests lysosomal dysfunction in the etiology of dementia with Lewy bodies. Human Molecular Genetics. 2014 Dec 1;23(23):6139–46.

31.

McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor JP, Weintraub D, et al. Diagnosis and management of dementia with Lewy bodies. Neurology. 2017 Jul 4;89(1):88–100.

32.

Weil RS, Lashley TL, Bras J, Schrag AE, Schott JM. Current concepts and controversies in

the pathogenesis of Parkinson's disease dementia and Dementia with Lewy Bodies. F1000Research. 2017 Aug 30;6.

33.

Woollacott IOC, Rohrer JD. The clinical spectrum of sporadic and familial forms of frontotemporal dementia. Journal of Neurochemistry. 2016 Aug;138:6–31.

34.

Gordon E, Rohrer JD, Fox NC. Advances in neuroimaging in frontotemporal dementia. Journal of Neurochemistry. 2016 Aug;138:193–210.

35.

Ahmed RM, Devenney EM, Irish M, Ittner A, Naismith S, Ittner LM, et al. Neuronal network disintegration: common pathways linking neurodegenerative diseases. Journal of Neurology, Neurosurgery & Psychiatry. 2016 Nov;87(11):1234–41.

36.

Fletcher PD, Warren JD. Semantic Dementia: a specific network-opathy. Journal of Molecular Neuroscience. 2011 Nov;45(3):629–36.

37.

Goll JC, Crutch SJ, Loo JHY, Rohrer JD, Frost C, Bamiou DE, et al. Non-verbal sound processing in the primary progressive aphasia. Brain. 2010 Jan;133(1):272–85.

38.

Goll JC, Ridgway GR, Crutch SJ, Theunissen FE, Warren JD. Nonverbal sound processing in semantic dementia: A functional MRI study. NeuroImage. 2012 May;61(1):170–80.

39.

Gorno-Tempini ML, Hillis AE, Weintraub S, Kertesz A, Mendez M, Cappa SF, et al.

Classification of primary progressive aphasia and its variants. *Neurology*. 2011 Mar 15;76(11):1006–14.

40.

Grossman M. The non-fluent/agrammatic variant of primary progressive aphasia. *The Lancet Neurology*. 2012 Jun;11(6):545–55.

41.

Leyton CE, Hodges JR, McLean CA, Kril JJ, Piguet O, Ballard KJ. Is the logopenic-variant of primary progressive aphasia a unitary disorder? *Cortex*. 2015 Jun;67:122–33.

42.

Marshall CR, Hardy CJD, Volkmer A, Russell LL, Bond RL, Fletcher PD, et al. Primary progressive aphasia: a clinical approach. *Journal of Neurology*. 2018 Jun;265(6):1474–90.

43.

Rohrer JD, Knight WD, Warren JE, Fox NC, Rossor MN, Warren JD. Word-finding difficulty: a clinical analysis of the progressive aphasia. *Brain*. 2007 Dec 3;131(1):8–38.

44.

Rohrer JD, Ridgway GR, Crutch SJ, Hailstone J, Goll JC, Clarkson MJ, et al. Progressive logopenic/phonological aphasia: Erosion of the language network. *NeuroImage*. 2010 Jan;49(1):984–93.

45.

Rohrer JD, Rossor MN, Warren JD. Syndromes of nonfluent primary progressive aphasia: A clinical and neurolinguistic analysis. *Neurology*. 2010 Aug 17;75(7):603–10.

46.

Rohrer JD, Sauter D, Scott S, Rossor MN, Warren JD. Receptive prosody in nonfluent primary progressive aphasia. *Cortex*. 2012 Mar;48(3):308–16.

47.

Warren JD, Rohrer JD, Rossor MN. Frontotemporal dementia. *BMJ*. 2013 Aug 20;347(aug123):f4827–f4827.

48.

Lynch DS, Rodrigues Brandão de Paiva A, Zhang WJ, Bugiardi E, Freua F, Tavares Lucato L, et al. Clinical and genetic characterization of leukoencephalopathies in adults. *Brain*. 2017 May 1;140(5):1204–11.

49.

Hollak CEM, Lachmann R, editors. Inherited metabolic disease in adults: a clinical guide [Internet]. [New York]: Oxford University Press; 2016. Available from: [http://ucl.alma.exlibrisgroup.com/view/action/uresolver.do?operation=resolveService&package\\_service\\_id=3043210560004761&institutionId=4761&customerId=4760](http://ucl.alma.exlibrisgroup.com/view/action/uresolver.do?operation=resolveService&package_service_id=3043210560004761&institutionId=4761&customerId=4760)

50.

Devenney E, Vucic S, Hodges JR, Kiernan MC. Motor neuron disease-frontotemporal dementia: a clinical continuum. *Expert Review of Neurotherapeutics*. 2015 May 4;15(5):509–22.

51.

Strong MJ, Abrahams S, Goldstein LH, Woolley S, Mclaughlin P, Snowden J, et al. Amyotrophic lateral sclerosis - frontotemporal spectrum disorder (ALS-FTSD): Revised diagnostic criteria. *Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration*. 2017 Apr 3;18(3-4):153–74.

52.

Iranzo A, Fernández-Arcos A, Tolosa E, Serradell M, Molinuevo JL, Valldeoriola F, et al. Neurodegenerative Disorder Risk in Idiopathic REM Sleep Behavior Disorder: Study in 174 Patients. *PLoS ONE*. 2014 Feb 26;9(2).

53.

Kielb SA, Ancoli-Israel S, Rebok GW, Spira AP. Cognition in Obstructive Sleep Apnea-Hypopnea Syndrome (OSAS): Current Clinical Knowledge and the Impact of Treatment. *NeuroMolecular Medicine*. 2012 Sep;14(3):180–93.

54.

Mander BA, Winer JR, Jagust WJ, Walker MP. Sleep: A Novel Mechanistic Pathway, Biomarker, and Treatment Target in the Pathology of Alzheimer's Disease? *Trends in Neurosciences*. 2016 Aug;39(8):552–66.

55.

McCarter SJ, St. Louis EK, Boeve BF. Sleep Disturbances in Frontotemporal Dementia. *Current Neurology and Neuroscience Reports*. 2016 Sep;16(9).

56.

Ooms S, Ju YE. Treatment of Sleep Disorders in Dementia. *Current Treatment Options in Neurology*. 2016 Sep;18(9).

57.

Hardy CJD, Marshall CR, Golden HL, Clark CN, Mummery CJ, Griffiths TD, et al. Hearing and dementia. *Journal of Neurology*. 2016 Nov;263(11):2339–54.

58.

Livingston G, Sommerlad A, Orgeta V, Costafreda SG, Huntley J, Ames D, et al. Dementia prevention, intervention, and care. *The Lancet*. 2017 Dec;390(10113):2673–734.

59.

Goll JC, Crutch SJ, Warren JD. Central auditory disorders: toward a neuropsychology of auditory objects. *Current Opinion in Neurology*. 2010 Dec;23(6):617–27.

60.

Husain M. Oxford textbook of cognitive neurology and dementia [Internet]. Husain M, Schott JM, Kennard C, editors. [Oxford]: Oxford University Press; 2016. Available from: [http://ucl.alma.exlibrisgroup.com/view/action/uresolver.do?operation=resolveService&package\\_service\\_id=3119511110004761&institutionId=4761&customerId=4760](http://ucl.alma.exlibrisgroup.com/view/action/uresolver.do?operation=resolveService&package_service_id=3119511110004761&institutionId=4761&customerId=4760)

61.

Blennow K, Hardy J, Zetterberg H. The Neuropathology and Neurobiology of Traumatic Brain Injury. *Neuron*. 2012 Dec;76(5):886–99.

62.

Smith DH, Johnson VE, Stewart W. Chronic neuropathologies of single and repetitive TBI: substrates of dementia? *Nature Reviews Neurology*. 2013 Apr;9(4):211–21.

63.

McKee AC, Stein TD, Nowinski CJ, Stern RA, Daneshvar DH, Alvarez VE, et al. The spectrum of disease in chronic traumatic encephalopathy. *Brain*. 2013 Jan;136(1):43–64.

64.

Fleminger S. Head injury as a risk factor for Alzheimer's disease: the evidence 10 years on; a partial replication. *Journal of Neurology, Neurosurgery & Psychiatry*. 2003 Jul 1;74(7):857–62.

65.

Scott G, Ramlackhansingh AF, Edison P, Hellyer P, Cole J, Veronese M, et al. Amyloid pathology and axonal injury after brain trauma. *Neurology*. 2016 Mar 1;86(9):821–8.

66.

Hereditary and sporadic beta-amyloidoses [Internet]. Available from: <https://www.bioscience.org/2013/v18/af/4173/fulltext.htm>

67.

Johnson GVW. Tau phosphorylation in neuronal cell function and dysfunction. *Journal of Cell Science*. 2004 Nov 15;117(24):5721–9.

68.

Revesz T, Holton JL, Lashley T, Plant G, Frangione B, Rostagno A, et al. Genetics and molecular pathogenesis of sporadic and hereditary cerebral amyloid angiopathies. *Acta Neuropathologica*. 2009 Jul;118(1):115–30.

69.

Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW, et al. National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. *Acta Neuropathologica*. 2012 Jan;123(1):1–11.

70.

Thal DR. Neurodegeneration in Normal Brain Aging and Disease. *Science of Aging Knowledge Environment*. 2004 Jun 9;2004(23):pe26–pe26.

71.

Braak H, Braak E. Staging of alzheimer's disease-related neurofibrillary changes. *Neurobiology of Aging*. 1995 May;16(3):271–8.

72.

Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD): Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. *Neurology*. 1991 Apr 1;41(4):479–479.

73.

Montine TJ, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Dickson DW, et al. National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. *Acta Neuropathologica*. 2012 Jan;123(1):1–11.

74.

Dobson R, Alvares D. The difficulties with vitamin B. *Practical Neurology*. 2016 Aug;16(4):308–11.

75.

Jonathan Carr. Neurosyphilis. *Practical Neurology* [Internet]. 2003 Dec 1;3:328–41. Available from: <https://pn.bmj.com/content/3/6/328>

76.

Graus F, Titulaer MJ, Balu R, Benseler S, Bien CG, Cellucci T, et al. A clinical approach to diagnosis of autoimmune encephalitis. *The Lancet Neurology*. 2016 Apr;15(4):391–404.

77.

Salvarani C, Brown RD, Hunder GG. Adult primary central nervous system vasculitis. *The Lancet*. 2012 Aug;380(9843):767–77.

78.

Halperin JJ, Kurlan R, Schwalb JM, Cusimano MD, Gronseth G, Gloss D. Practice guideline: Idiopathic normal pressure hydrocephalus: Response to shunting and predictors of response. *Neurology*. 2015 Dec 8;85(23):2063–71.

79.

Arash Asher. The effect of cancer treatment on cognitive function. undefined [Internet]. Available from: <https://www.semanticscholar.org/paper/The-effect-of-cancer-treatment-on-cognitive-Asher-Myers/6bdd550dab6cfad0714aa76dd2ee439ad983e4be>

80.

Graus F, Titulaer MJ, Balu R, Benseler S, Bien CG, Cellucci T, et al. A clinical approach to diagnosis of autoimmune encephalitis. *The Lancet Neurology*. 2016 Apr;15(4):391–404.

81.

Cognitive Impairment Associated with Cancer: A Brief Review. *Innovations in Clinical Neuroscience* [Internet]. 2018;15(1–2). Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5819720/>

82.

Haddow LJ, Cartledge JD, Manji H. HIV and the brain: from AIDS to old age. *Clinical Medicine*. 2013 Dec 1;13(Suppl\_6):s24–8.

83.

Nightingale S, Michael BD, Defres S, Benjamin LA, Solomon T. Test them all; an easily diagnosed and readily treatable cause of dementia with life-threatening consequences if missed. *Practical Neurology*. 2013 Dec;13(6):354–6.

84.

HIV in the United Kingdom 2016 infographic [Internet]. Available from: <https://www.gov.uk/government/publications/hiv-in-the-united-kingdom>

85.

Itzhaki RF, Lathe R, Balin BJ, Ball MJ, Bearer EL, Braak H, et al. Microbes and Alzheimer's Disease. *Journal of Alzheimer's Disease*. 2016 Apr 12;51(4):979–84.

86.

Nightingale S, Winston A, Letendre S, Michael BD, McArthur JC, Khoo S, et al. Controversies in HIV-associated neurocognitive disorders. *The Lancet Neurology*. 2014

Nov;13(11):1139–51.

87.

Richard W. Price and Bruce J. Brew. The AIDS Dementia Complex. The Journal of Infectious Diseases [Internet]. 1988;158(5). Available from:  
[https://www.jstor.org/stable/30136610?seq=1#metadata\\_info\\_tab\\_contents](https://www.jstor.org/stable/30136610?seq=1#metadata_info_tab_contents)

88.

UK National Guidelines for HIV Testing 2008 [Internet]. Available from:  
<https://www.bhiva.org/HIV-testing-guidelines>

89.

Zhou L, Miranda-Saksena M, Saksena NK. Viruses and neurodegeneration. Virology Journal. 2013;10(1).

90.

De Chiara G, Marcocci ME, Sgarbanti R, Civitelli L, Ripoli C, Piacentini R, et al. Infectious Agents and Neurodegeneration. Molecular Neurobiology. 2012 Dec;46(3):614–38.

91.

Wendorf KA, Winter K, Zipprich J, Schechter R, Hacker JK, Preas C, et al. Subacute Sclerosing Panencephalitis: The Devastating Measles Complication That Might Be More Common Than Previously Estimated. Clinical Infectious Diseases. 2017 Jul 15;65(2):226–32.

92.

Ghanem KG. REVIEW: Neurosyphilis: A Historical Perspective and Review. CNS Neuroscience & Therapeutics. 2010 Oct;16(5):e157–68.

93.

Somasundaram O. Neuro syphilis: Portrayals by Sir Arthur Conan Doyle. *Indian Journal of Psychiatry*. 2009;51(3).

94.

Hachinski V, Iadecola C, Petersen RC, Breteler MM, Nyenhuis DL, Black SE, et al. National Institute of Neurological Disorders and Stroke–Canadian Stroke Network Vascular Cognitive Impairment Harmonization Standards. *Stroke*. 2006 Sep;37(9):2220–41.

95.

Gorelick PB, Scuteri A, Black SE, DeCarli C, Greenberg SM, Iadecola C, et al. Vascular Contributions to Cognitive Impairment and Dementia. *Stroke*. 2011 Sep;42(9):2672–713.

96.

Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. *The Lancet*. 2001 Jan;357(9251):169–75.

97.

Leys D, Hénon H, Mackowiak-Cordoliani MA, Pasquier F. Poststroke dementia. *The Lancet Neurology*. 2005 Nov;4(11):752–9.

98.

O'Brien JT, Thomas A. Vascular dementia. *The Lancet*. 2015 Oct;386(10004):1698–706.